MDGL

#806
Madrigal Pharmaceuticals, Inc. - Common Stock
543.6 9 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
543.69
543.69
Jahresspanne
393.61
614.36
Tagesänderung
+0.89%
Monatliche Änderung
+0.39%
6 month change
+26.37%
Jahresänderung
+28.35%
Vorheriger Schlusskurs
538.8 8
Open
543.6 9
Tief
543.6 9
Hoch
543.6 9
Volumen
65
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
MADRIGAL PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
MADRIGAL PHARMACEUTICALS, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
MADRIGAL PHARMACEUTICALS, INC. annual report, FY2025
10-K

MADRIGAL PHARMACEUTICALS, INC. current report, Q1 FY2026

Full document

Business Context and Reporting Period

Company: Madrigal Pharmaceuticals, Inc. (MDGL)
Filing Type: Form 8-K (Current Report)
Report Date: February 19, 2026
Reporting Period: Fiscal quarter and full year ended December 31, 2025.

This filing serves as a notification that the Company issued a press release announcing its financial results for the period ended December 31, 2025. The detailed financial data is contained in the press release furnished as Exhibit 99.1.

Key Financial Metrics

The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. Consequently, the following metrics are not available in this document:

  • Revenue: Not provided in filing text.
  • Profit/Loss: Not provided in filing text.
  • Cash Flow: Not provided in filing text.
  • Margins: Not provided in filing text.
  • Debt and Liquidity: Not provided in filing text.

Material Changes

The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year or quarter-over-quarter analysis.

Guidance, Outlook, and Risks

Management Commentary: The filing confirms the issuance of a press release regarding financial results but does not include the text of the commentary, guidance, or outlook within this document.
Risks and Contingencies: No specific risks or contingencies are detailed in this cover sheet. The filing includes a standard disclaimer stating that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act unless expressly incorporated by reference.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release dated February 19, 2026) for actual revenue, net income, and cash position figures.
  • Verify the specific performance of the Company's drug pipeline and commercial products mentioned in the press release.
  • Check for any updated forward-looking guidance or clinical trial milestones announced in the press release.
  • Confirm the Company's liquidity position and cash runway as detailed in the full financial statements referenced in the press release.

Nachrichten